ATE440617T1 - Unterdrückung von allergischen reaktionen durch transkutane verabreichung von allergenen zusammen mit oder fusioniert mit toxinuntereinheiten oder deren fragmenten - Google Patents
Unterdrückung von allergischen reaktionen durch transkutane verabreichung von allergenen zusammen mit oder fusioniert mit toxinuntereinheiten oder deren fragmentenInfo
- Publication number
- ATE440617T1 ATE440617T1 AT02751507T AT02751507T ATE440617T1 AT E440617 T1 ATE440617 T1 AT E440617T1 AT 02751507 T AT02751507 T AT 02751507T AT 02751507 T AT02751507 T AT 02751507T AT E440617 T1 ATE440617 T1 AT E440617T1
- Authority
- AT
- Austria
- Prior art keywords
- ctb
- responses
- allergen
- administration
- found
- Prior art date
Links
- 239000013566 allergen Substances 0.000 title abstract 6
- 206010020751 Hypersensitivity Diseases 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 230000001629 suppression Effects 0.000 title 1
- 239000003053 toxin Substances 0.000 title 1
- 231100000765 toxin Toxicity 0.000 title 1
- 230000004044 response Effects 0.000 abstract 4
- 230000005875 antibody response Effects 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
- 230000009885 systemic effect Effects 0.000 abstract 2
- 241000699670 Mus sp. Species 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000000763 evoking effect Effects 0.000 abstract 1
- 229930186900 holotoxin Natural products 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000001165 lymph node Anatomy 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 230000009696 proliferative response Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29314201P | 2001-05-23 | 2001-05-23 | |
| PCT/IB2002/003053 WO2002093998A2 (en) | 2001-05-23 | 2002-05-23 | Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE440617T1 true ATE440617T1 (de) | 2009-09-15 |
Family
ID=23127818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02751507T ATE440617T1 (de) | 2001-05-23 | 2002-05-23 | Unterdrückung von allergischen reaktionen durch transkutane verabreichung von allergenen zusammen mit oder fusioniert mit toxinuntereinheiten oder deren fragmenten |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050074462A1 (de) |
| EP (1) | EP1450855B1 (de) |
| JP (1) | JP4339598B2 (de) |
| AT (1) | ATE440617T1 (de) |
| AU (1) | AU2002339121B2 (de) |
| CA (1) | CA2447795A1 (de) |
| DE (1) | DE60233519D1 (de) |
| DK (1) | DK1450855T3 (de) |
| WO (1) | WO2002093998A2 (de) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1372708T3 (da) * | 2001-02-13 | 2008-10-20 | Us Gov Sec Army | Vaccine til transkutan immunisering mod rejsediarre |
| FR2822049B1 (fr) | 2001-03-13 | 2003-08-01 | Dbv Medica 1 | Patch destine notamment a depister l'etat de sensibilisation d'un sujet a un allergene, procede de fabrication et utilisation |
| US7635488B2 (en) | 2001-03-13 | 2009-12-22 | Dbv Technologies | Patches and uses thereof |
| US20040137004A1 (en) * | 2002-03-19 | 2004-07-15 | Glenn Gregory M | Patch for transcutaneous immunization |
| JP2007525436A (ja) * | 2003-03-24 | 2007-09-06 | マーシア・ファーマ・インコーポレイテッド | 炎症症状を処置および予防するための方法および組成物 |
| CN1852701A (zh) * | 2003-09-17 | 2006-10-25 | 婴儿保健公司 | 防止过敏的方法及装置 |
| CA2630840A1 (en) * | 2005-11-23 | 2007-05-31 | Universitaet Zuerich | Allergy treatment by epicutaneous allergen administration |
| US8449894B2 (en) * | 2006-05-26 | 2013-05-28 | City Of Hope | Aspergillus vaccine preparation and methods of making and using thereof |
| JP5127208B2 (ja) * | 2006-08-24 | 2013-01-23 | 独立行政法人理化学研究所 | 組換えスギ花粉抗原融合遺伝子と可溶性産物の製造方法 |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| JPWO2009004900A1 (ja) * | 2007-06-29 | 2010-08-26 | 学校法人 城西大学 | ユビキノン含有免疫アジュバント |
| FR2924350B1 (fr) | 2007-12-03 | 2010-08-13 | Dbv Tech | Procede et compositions pour la vaccination par voie cutanee |
| FR2924349B1 (fr) | 2007-12-03 | 2010-01-01 | Dbv Tech | Methode de desensibilitation aux allergenes |
| DE102008006394A1 (de) * | 2008-01-28 | 2009-07-30 | Beiersdorf Ag | Verwendung von Wirkstoffkomplexen aus Panthenol, Glycerin, Citrat und/oder Bisabolol gegen Pollenallergien |
| EP2305292A4 (de) | 2008-08-01 | 2013-02-20 | So Pharmaceutical Corp | Transdermales immunisierungsmittel vom s/o-typ |
| US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
| RU2593715C2 (ru) | 2010-09-15 | 2016-08-10 | Рэндэлл Дж. МРСНИ | Системы и способы доставки биоактивных средств с применением транспортных последовательностей, происходящих от бактериального токсина |
| US9574004B2 (en) | 2012-08-21 | 2017-02-21 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
| PT3889181T (pt) | 2012-09-07 | 2024-05-29 | Regeneron Pharma | Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração |
| TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法 |
| TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| WO2015130975A1 (en) | 2014-02-28 | 2015-09-03 | Regeneron Pharmaceuticals, Inc. | Methods for treating skin infection by administering an il-4r antagonist |
| CN106470707A (zh) | 2014-05-07 | 2017-03-01 | 应用分子运输有限责任公司 | 用于口服递送生物活性货物的cholix毒素衍生的融合分子 |
| AU2015346150B2 (en) | 2014-11-14 | 2021-08-19 | Regeneron Pharmaceuticals, Inc. | Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist |
| HUE067888T2 (hu) | 2016-09-01 | 2024-11-28 | Regeneron Pharma | Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával |
| WO2018057776A1 (en) | 2016-09-22 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
| CN110022886A (zh) * | 2016-10-05 | 2019-07-16 | 王天欣 | 一种治疗自身免疫性疾病和过敏的方法和试剂 |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
| CA3079946A1 (en) | 2017-10-30 | 2019-05-09 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
| US11292847B2 (en) | 2018-05-13 | 2022-04-05 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an IL-4R inhibitor |
| EP4083058A3 (de) | 2018-11-07 | 2023-01-11 | Applied Molecular Transport Inc. | Verabreichungskonstrukte für die transzytose und zugehörige verfahren |
| CA3132587A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| BR112022000740A2 (pt) | 2019-07-16 | 2022-07-05 | Sanofi Biotechnology | Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r |
| US11504426B2 (en) | 2019-08-05 | 2022-11-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist |
| WO2021026205A1 (en) | 2019-08-05 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| MX2022001975A (es) | 2019-08-16 | 2022-03-11 | Applied Molecular Transport Inc | Composiciones, formulaciones y produccion y purificacion de interleucinas. |
| US20230292707A1 (en) * | 2022-03-16 | 2023-09-21 | Allibre Animal LLC | Systems and methods for administering dermal and transdermal immunotherapy topical application compounds to animals |
| EP4417215A1 (de) * | 2023-02-20 | 2024-08-21 | Sorbonne Universite | Interleukin-1 zur behandlung und vorbeugung von allergien |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2227861B1 (de) * | 1973-05-04 | 1976-07-02 | Anvar | |
| US5980898A (en) * | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| US7097845B2 (en) * | 1997-04-23 | 2006-08-29 | Jacob Sten Petersen | Combinations of antigen and mucosal binding component for inducing specific immunological tolerance |
| ATE365050T1 (de) * | 1998-02-25 | 2007-07-15 | Us Gov Sec Army | Verwendung von hautpenetrationsförderern und für die zerstörung der oberen hautschichten geeigneten mitteln zur erhöhung der transkutanen immunantwort |
| AU748565B2 (en) * | 1998-06-23 | 2002-06-06 | Board Of Trustees Of The Leland Stanford Junior University | Adjuvant therapy |
-
2002
- 2002-05-23 CA CA002447795A patent/CA2447795A1/en not_active Abandoned
- 2002-05-23 US US10/477,909 patent/US20050074462A1/en not_active Abandoned
- 2002-05-23 EP EP02751507A patent/EP1450855B1/de not_active Expired - Lifetime
- 2002-05-23 DE DE60233519T patent/DE60233519D1/de not_active Expired - Lifetime
- 2002-05-23 AT AT02751507T patent/ATE440617T1/de not_active IP Right Cessation
- 2002-05-23 DK DK02751507T patent/DK1450855T3/da active
- 2002-05-23 JP JP2002590728A patent/JP4339598B2/ja not_active Expired - Fee Related
- 2002-05-23 AU AU2002339121A patent/AU2002339121B2/en not_active Ceased
- 2002-05-23 WO PCT/IB2002/003053 patent/WO2002093998A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20050074462A1 (en) | 2005-04-07 |
| WO2002093998A2 (en) | 2002-11-28 |
| WO2002093998A9 (en) | 2005-05-26 |
| EP1450855A2 (de) | 2004-09-01 |
| CA2447795A1 (en) | 2002-11-28 |
| JP4339598B2 (ja) | 2009-10-07 |
| EP1450855B1 (de) | 2009-08-26 |
| DK1450855T3 (da) | 2010-01-11 |
| DE60233519D1 (de) | 2009-10-08 |
| JP2004536804A (ja) | 2004-12-09 |
| AU2002339121B2 (en) | 2007-03-22 |
| WO2002093998A3 (en) | 2004-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE440617T1 (de) | Unterdrückung von allergischen reaktionen durch transkutane verabreichung von allergenen zusammen mit oder fusioniert mit toxinuntereinheiten oder deren fragmenten | |
| McNeela et al. | A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery | |
| Hjelm et al. | TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines | |
| WO2004016750A3 (en) | FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | |
| DE60141773D1 (de) | Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren | |
| BRPI0411784A (pt) | anticorpos contra interleucina -22 e usos para os mesmos | |
| CY1105216T1 (el) | Συστημα μικροβιακης παροχης | |
| Odutola et al. | Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2–4 years: A phase II randomized study | |
| IL211037A (en) | Antigen @ reactant @ with @ serum @ hyper | |
| BR0313492A (pt) | Formulação de anticorpos humanos para tratar distúrbios associados ao tnf-alfa | |
| BR0207283A (pt) | Anticorpos anti-egfr modificados com imunogenicidade reduzida | |
| WO2023147092A3 (en) | Coronavirus vaccine | |
| WO2023012652A3 (en) | Hypoallergenic peanut allergens, production and use thereof | |
| ATE458496T1 (de) | Hiv-vakzine und anwendungsverfahren | |
| Gwinn et al. | A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen | |
| WO2003089584A3 (en) | Use of parapox b2l protein to modify immune responses to administered antigens | |
| Gu et al. | Increased potency of BioThrax® anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109 | |
| DK0536302T3 (da) | Forbedrede adjuvanser og vacciner | |
| DE60109180D1 (de) | Parietaria judaica ns-ltp-antigenvarianten, entsprechende pharmazeutische zusammensetzungen und ihre verwendung | |
| WO1999025823A3 (en) | Recombinant allergen with reduced enzymatic activity | |
| Parker et al. | Respiratory infections due to Streptococcus pneumoniae and the influenza virus in South Africans undertaking the Hajj | |
| Tabatabaian et al. | Allergic rhinitis management: what’s next? | |
| Larsen et al. | Adjuvant effect of quaternary ammonium compounds in a murine model | |
| Bakir et al. | Heat-killed Mycobacterium bovis-bacillus Calmette Guerin-suppressed total serum IgE response in ovalbumin-sensitized newborn mice | |
| Griffin et al. | Protective efficacy of a recombinant plague vaccine when co-administered with another sub-unit or live attenuated vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |